Bavarian Nordic: Progressing At Cruising Speed
Following a $100m private placement, Bavarian Nordic (CO:BAVA) is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by...
Following a $100m private placement, Bavarian Nordic (CO:BAVA) is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by...
The biotech space has been a rough environment in which to pull off an initial public offering this year. A host of companies have ditched their offerings last minute, with...
The current weak US IPO conditions have resulted in a slight change of plan for Bavarian Nordic (CO:BAVA). It recently shelved its US listing plans and instead completed a private...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,314.77 | 2,335.00 | 2,308.28 | +7.94 | +0.34% | 1.33M | NASDAQ | |||
| 315.02 | 321.06 | 314.49 | -3.34 | -1.05% | 15.56M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 226.78 | 228.91 | 226.73 | -1.12 | -0.49% | 7.23M | NYSE | |||
| 1.20 | 1.20 | 1.13 | +0.1200 | +11.11% | 18.34M | NYSE | |||
| 41.84 | 44.40 | 40.97 | -1.56 | -3.59% | 8.37M | NASDAQ | |||
| 14.94 | 15.02 | 14.83 | -0.23 | -1.52% | 2.23M | NYSE | |||
| 0.7995 | 0.00 | 0.00 | -0.0055 | -0.68% | 766.48K | NYSE | |||
| 7.30 | 7.30 | 7.20 | +0.05 | +0.69% | 4.96M | NYSE | |||
| 69.76 | 70.71 | 69.34 | -2.34 | -3.25% | 2.06M | NYSE | |||
| 72.77 | 75.21 | 72.62 | -1.25 | -1.69% | 981.47K | NASDAQ | |||
| 77.73 | 81.75 | 76.59 | -2.00 | -2.51% | 605.93K | NASDAQ | |||
| 195.63 | 203.33 | 194.95 | -4.35 | -2.18% | 5.88M | NASDAQ | |||
| 31.23 | 31.50 | 31.07 | +0.34 | +1.10% | 1.69M | NYSE | |||
| 9.74 | 10.18 | 9.33 | +0.27 | +2.85% | 609.99K | NASDAQ |
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.